Table 4.
MDA-MB-231 GEPs IPA analysis
| IPA analysis of GEP IR induced in MDA-MB-231 breast cancer cell line | |||||
| Type of radiation treatment (particle type) | Top canonical pathway | Genes involved | p value | Overlap | % |
| e- | Tec kinase signaling | BLK; GNAO1; GNAZ; GNG13; PIK3R3; PTPN11:; STAT3; TNFRSF2 | 6.77E-03 | 4,8/162 | 4.9 |
| Histidine degradation III | FTCD; MTHFD2L | 7.61E-03 | 2/8 | 25 | |
| Acute phase response signaling | CD; IL-; IL36G; PIK3R3:PTPN11; RBP5; SERPIND; STAT3 | 7.79E-03 | 8/166 | 4,8 | |
| Role of Jak family kinase in IL-6-type cytokine signaling | IL-6; PTPN11; STAT3 | 8.59E-03 | 3/25 | 12 | |
| Regulation of the epithelial–mesenchymal transition pathway | EGR1; FZD4; ID2; PIK3R3PTPN11; STAT3; ZEB1; ZEB2 | 1.35E-02 | 8/183 | 4,4 | |
| p+ | IL-17A signaling | CXCL1; CXCL3; CXCL8; IL-17; IL17RA | 3.18E-04 | 5/13 | 38.5 |
| IL-17A signaling in gastric CELLS | CXCL1; CXCL8; FOS; IL17A; IL17RA; TNF | 1.36E-03 | 6/25 | 24 | |
| Altered T-cell and B-cell signaling in rheumatoid arthritis | HLA-DOA; HLA-DQB1; IL37; IL17A; IL36G; LTA; SLAMF1; TNF; TNFRSF17; TNFRSF13C;TRAF3 | 2.01E-03 | 11/78 | 14.1 | |
| CD40 signaling | FOS; ICAM1; JAK3; LTA;MAP2K6; PTGS1; PTGS2; STAT3; TNFAIP3; TRAF3 | 5.78E-03 | 10/77 | 13 | |
| Airway pathology in chronic obstructive pulmonary disease | CXCL3; CXCL8; TNF | 6.18E-03 | 3/8 | 37.5 | |
| e-/p+ (common genes) | TR/RXR activation | ATP2A1; RAB3B; SLC16A2 | 2.27E-02 | 3/98 | 3.1 |
| Transcriptional regulatory network in mbryonic stem cells | PAX6; STAT3 | 2.52E-02 | 2/40 | 5 | |
| Mouse embryonic stem cell pluripotency | FZD4; ID2; STAT3 | 2.78E-02 | 3/106 | 2,8 | |
| Agranulocyte adhesion and diapedesis | CD34; IL36G; MMP15; MSN | 2.96E-02 | 4/189 | 2,1 | |
| Regulation of the epithelial-mesenchymal transition pathway | FZD4;ID2;STAT3;ZEB2 | 2.96E-02 | 4/189 | 2,1 | |